GlassScriptPhysician profile
Emily Quintero
NPI 1609455922
$2,561.08
in general payments reported to CMS, 2019-2025
30 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.36 · 2023: $130 · 2024: $428 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $487.99 | 2024-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $359.02 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $183.68 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Glaxosmithkline, LLC. | $171.80 | 2023-2025 | Arexvy, Shingrix |
| Beta Bionics, INC. | $151.40 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Exact Sciences Corporation | $132.83 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $128.60 | 2024-2025 | |
| Averitas Pharma INC. | $97.77 | 2024 | Qutenza |
| Corcept Therapeutics | $92.39 | 2024-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $84.36 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $65.23 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $64.98 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $58.18 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $57.16 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $51.31 | 2025 | Farxiga, Airsupra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $48.60 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $38.90 | 2025 | Gardasil 9, Capvaxive |
| Tempus Ai, INC | $28.71 | 2024 | |
| Cleerly, INC. | $28.41 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Madrigal Pharmaceuticals | $27.87 | 2025 | Rezdiffra |
| Dynavax Technologies Corporation | $26.37 | 2025 | Heplisav-B |
| Ibsa Pharma INC. | $24.87 | 2025 | Tirosint, Licart, Flector |
| Hologic Sales and Service, LLC | $22.86 | 2025 | Aptima, Thinprep 2000 Processor |
| Dexcom, INC. | $21.45 | 2025 | Dexcom G6 Transmitter |
| Alcon Vision LLC | $20.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.45 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.96 | 2024 | Synjardy, Jardiance |
| Antares Pharma, INC. | $17.37 | 2025 | Xyosted |
| Rgh Enterprises LLC | $17.32 | 2024 | |
| Abbvie INC. | $13.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Quintero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.